Key result
Early glycemic control reduces cardiac autonomic neuropathy severity and delays other diabetic complications.
Why the study?
Diabetic autonomic neuropathy clinically involves multiple systems and accelerates major complications, requiring a practical approach to detecting and investigating its manifestations.
This review highlights the importance of early detection and glycemic control in managing diabetic autonomic neuropathy to reduce cardiovascular morbidity and mortality.
Supports glycemic control in diabetes; leaves open need for prospective trials on cardiac autonomic outcomes.
The manifestations of diabetic autonomic neuropathy (DAN) are protean and clinically involve multiple systems, including the cardiovascular system, the gastrointestinal system, the genitourinary system as well as the sweat glands (sudomotor dysfunction) and the gallbladder. In addition, cardiac autonomic neuropathy (CAN) is associated with a correctible inability to appreciate and correct hypoglycaemia. While not a clinical problem, pupillary involvement should be the clue and the catalyst to investigate for other manifestations of DAN. This review outlines a practical approach to detecting and investigating the manifestations of DAN. Of particular importance is early detection of cardiovascular involvement where prompt therapy through glycaemic control can decrease the severity of CAN and decelerate the frequency and severity of retinopathy and nephropathy in addition to decreasing cardiovascular events and mortality. CAN also plays a role in accelerating other diabetic complications such as acute ischaemic stroke, heart failure, medial artery calcinosis, foot ulcers, peripheral artery disease and Charcot joints. Many therapies of DAN are available, which should not only decrease morbidity and mortality from DAN, but also improve the patient's quality of life. However, the therapies available are largely symptomatic.
No takes yet. Share an insight, caveat, or question.
David S.H. Bell (2023) conducted a review in Diabetic autonomic neuropathy. Glycaemic control and symptomatic therapies was evaluated. Early detection and prompt therapy through glycaemic control can decrease the severity of cardiac autonomic neuropathy and decelerate the frequency of other diabetic complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: